We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Blood Test Can Assess Risk of Type 2 Diabetes

By LabMedica International staff writers
Posted on 23 Feb 2024
Print article
Image: Jointly assessing biomarkers in a blood test could potentially predict type 2 diabetic risks (Photo courtesy of Edith Cowan University)
Image: Jointly assessing biomarkers in a blood test could potentially predict type 2 diabetic risks (Photo courtesy of Edith Cowan University)

The chronic and progressive nature of diabetes, along with its associated comorbidities, underscores the critical need for prompt action to tackle this significant health concern. Currently, the most widely utilized biomarker to forecast the risk of type 2 diabetes is high-sensitivity C-reactive protein (CRP). Recent studies, however, have indicated that assessing a combination of biomarkers, rather than evaluating each one separately, could enhance the ability to predict the risk of diabetes and its complications. Now, a new study has found that a blood test for jointly assessing biomarkers could potentially be used to predict a patient's risk of type 2 diabetes.

In the study, researchers from Edith Cowan University (Joondalup, Australia) examined the relationship between systemic inflammation, measured through a combined analysis of high-sensitivity CRP and another biomarker known as the monocyte to high-density lipoprotein ratio (MHR), and the onset of type 2 diabetes. This study tracked over 40,800 participants who did not have diabetes for nearly a decade, during which more than 4,800 participants developed the condition. Among those who developed type 2 diabetes, a significant interaction between MHR and CRP was noted. Specifically, as the MHR increased within each CRP category, so did the risk of developing type 2 diabetes; simultaneous increases in MHR and CRP were linked to significantly higher rates and risks of developing diabetes.

Moreover, the study revealed that the link between chronic inflammation (as indicated by the combined MHR and CRP levels) and new cases of diabetes was strongly dependent on age and sex and was affected by conditions such as hypertension, high cholesterol, or prediabetes. Adding MHR and CRP to the clinical risk model markedly enhanced the prediction of new diabetes cases. The study also found that women were at a higher risk of type 2 diabetes due to joint increases in CRP and MHR, with sex hormones playing a role in these differences. These findings supported the role of chronic inflammation in the early development of diabetes and underscored the need for targeted attention.

While age and genetics are factors that cannot be modified, other risk factors can be altered through changes in lifestyle. Inflammation is heavily influenced by lifestyle and metabolic conditions, including diet, sleep disturbances, chronic stress, and imbalances in glucose and cholesterol. This suggests the potential benefits of monitoring metabolic conditions related to risk. The cost-effectiveness and widespread availability of combined MHR and CRP testing in current clinical practice make these measures a promising and convenient tool for predicting diabetes risk.

"Epidemiological evidence indicates a consistent increase in early-onset diabetes, especially in developing countries,” said ECU researcher Dan Wu. “Leveraging this age-specific association between chronic inflammation and type 2 diabetes may be a promising method for achieving early identification of at-risk young adults and developing personalized interventions."

Related Links:
Edith Cowan University

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Whole Blood-Based Controls
Lyphochek Hemoglobin A1C Linearity Set
New
hCG+β Automated Immunofluorescent Assay
B·R·A·H·M·S hCG+β KRYPTOR

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: Virtual birefringence imaging and histological staining of amyloid deposits in label-free tissue (Photo courtesy of Ozcan Research Group)

AI-Based Tissue Staining Detects Amyloid Deposits Without Chemical Stains or Polarization Microscopy

Systemic amyloidosis, a disorder characterized by the buildup of misfolded proteins in organs and tissues, presents significant diagnostic difficulties. The condition affects millions of people each year,... Read more

Industry

view channel
Image: The Scopio X100 and X100HT full-field digital cell morphology solution (Photo courtesy of Beckman Coulter)

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Since 2022, Beckman Coulter (Brea, CA, USA) and Scopio Labs (Tel Aviv, Israel) have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.